Neu­rol­o­gists val­ue speed and ef­fi­ca­cy over safe­ty for ALS pipeline drugs, study finds

Neu­rol­o­gists who were asked about new treat­ments for amy­otroph­ic lat­er­al scle­ro­sis (ALS) say they val­ue ef­fi­ca­cy and qual­i­ty-of-life im­prove­ments over safe­ty for drugs in de­vel­op­ment.

The typ­i­cal­ly rapid pro­gres­sion of the ter­mi­nal dis­ease is the chief fac­tor in the safe­ty sen­ti­ment, said Alis­sa Al­gar­in, se­nior in­sights an­a­lyst at Spher­ix Glob­al In­sights. As one neu­rol­o­gist told the sur­vey­ors: “In a con­di­tion like this, I’m more to­wards ef­fi­ca­cy be­cause if you’re dead it doesn’t mat­ter how safe the drug was.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER